Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: A multicenter retrospective study

Asher A. Chanan-Khan*, Jonathan L. Kaufman, Jayesh Mehta, Paul G. Richardson, Kena C. Miller, Sagar Lonial, Nikhil C. Munshi, Robert Schlossman, Joseph Tariman, Seema Singhal

*Corresponding author for this work

Research output: Contribution to journalArticle

214 Scopus citations

Abstract

Patients with multiple myeloma (MM) frequently present with concomitant renal dysfunction, and those requiring dialysis have particularly poor outcomes. Bortezomib is a reversible proteasome inhibitor with significant activity in MM. This retrospective case analysis evaluated the feasibility and activity of bortezomib-based therapy in MM patients (n = 24) requiring dialysis support for advanced renal failure. All but 1 patient were undergoing dialysis at the time of therapy. Patients received bortezomib alone or bortezomib-based combination therapy. Among 20 patients with available response data, overall response rate (complete response [CR] + partial response) was 75%, with 30% CR + near CR. One patient was spared dialysis, and 3 other patients became independent of dialysis following bortezomib-based treatment. These encouraging results suggest that bortezomib or bortezomib-based regimens can be used in MM patients requiring dialysis, with manageable toxicities. Further studies will more formally evaluate the impact of bortezomib-based regimens in this patient population.

Original languageEnglish (US)
Pages (from-to)2604-2606
Number of pages3
JournalBlood
Volume109
Issue number6
DOIs
StatePublished - Mar 15 2007

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Fingerprint Dive into the research topics of 'Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: A multicenter retrospective study'. Together they form a unique fingerprint.

  • Cite this

    Chanan-Khan, A. A., Kaufman, J. L., Mehta, J., Richardson, P. G., Miller, K. C., Lonial, S., Munshi, N. C., Schlossman, R., Tariman, J., & Singhal, S. (2007). Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: A multicenter retrospective study. Blood, 109(6), 2604-2606. https://doi.org/10.1182/blood-2006-09-046409